Skip to main content
SpringerLink
Log in

International Consensus Panel on the Treatment of Primary Breast Cancer V: Update 1998

  • Conference paper
Adjuvant Therapy of Primary Breast Cancer VI

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 152))

Abstract

Providing effective care for patients with early-stage breast cancer and designing appropriate recommendations for women at high risk of developing the disease are important public health goals. More than ever, progress requires integrated understanding based on the continuous interaction among several scientific and clinical disciplines. In February 1998, the 6th International Conference on Adjuvant Therapy of Primary Breast Cancer was held in St. Gallen, Switzerland. Knowledge of breast cancer genetics, diagnosis, and treatment has evolved since the 5th International Conference that was held in March 1995. At that time, a fundamental theme was to distinguish the role of prognostic factors used in the definition of risk from predictive factors used for the selection of adjuvant treatments according to therapeutic responsiveness (Goldhirsch et al. 1995). Also, at that time, the findings from the 1992 overview publication (Early Breast Cancer Trialists’ Collaborative Group 1992) that reported results on ovarian ablation, tamoxifen, and chemotherapy effects were being increasingly applied to justify adjuvant treatment for a wider spectrum of indications.

First published in: Journal of the National Cancer Institute, 1998, 90 (Nov. 4, 1998).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J for SWOG, ECOG, CALGB, NCCTG, and NCI-Canada (1997) Tamoxifen (T) versus cyclophosphamide, Adriamycin® and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+), node(+) breast cancer: a Southwest Oncology Group phase III Intergroup trial (SWOG-8814, INT-0100) [abstract 450]. Proc ASCO 16:128a

    Google Scholar 

  • Axelsson CK, Mouridsen HT, Zedeler K (1992) Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 28A:1415–1418

    Article  PubMed  CAS  Google Scholar 

  • Boccardo F, Amoroso D, Rubagotti A, Castagnetta L, Delia P, De Sanctis C et al for the GROCTA (1993) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: an update at 8 years of the first GROCTA trial. In: Salmon SE (ed) Adjuvant therapy of cancer VII. Lippincott, Philadelphia, pp 181–192

    Google Scholar 

  • Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542–547

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93–100

    PubMed  CAS  Google Scholar 

  • Bontenbal M, Foekens JA, Lamberts SW, de Jong FH, van Putten WL, Braun HJ et al (1998) Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer 77:115–122

    Article  PubMed  CAS  Google Scholar 

  • Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997–1003

    Article  PubMed  CAS  Google Scholar 

  • Chen MH, Chuang ML, Bornstein BA, Gelman R, Harris JR, Manning WJ (1997) Impact of respiratory maneuvers on cardiac volume within left-breast radiation portals. Circulation 96:3269–3272

    PubMed  CAS  Google Scholar 

  • Clark GM, Harvey JM, Osborne CK, Allred DC (1997) Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients. Proc ASCO 16 (abstr 454)

    Google Scholar 

  • Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647

    Article  PubMed  CAS  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:71–85

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348:1189–1196

    Article  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

    Article  Google Scholar 

  • Eisen T, Smith IE, Johnston S, Ellis PA, Prendiville J, Seymour MT et al (1998) Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infu-sional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 16:1350–1357

    PubMed  CAS  Google Scholar 

  • Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M et al (1998) Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16:107–114

    PubMed  CAS  Google Scholar 

  • Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL et al (1990) Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast & Bowel Projekt B-16. J Clin Oncol 8:1005–1018

    PubMed  CAS  Google Scholar 

  • Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Natl Cancer Inst 88:1529–1542

    Article  CAS  Google Scholar 

  • Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG et al (1997a) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493

    PubMed  CAS  Google Scholar 

  • Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL et al (1997b) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673–1682

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Brown A, Mamounas E, Wieand S, Fisher E, Robidoux A et al (1997c) Effect of preoperative therapy for primary breast cancer (BC) on local-regional disease, disease-free survival (DFS) and survival (S): results from NSABP B-18. Proc ASCO 16:127A (abstr 449)

    Google Scholar 

  • Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452

    PubMed  CAS  Google Scholar 

  • Gelber RD, Cole BH, Goldhirsch A, Rose C, Fisher B, Osborne CK et al (1996) Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 347:1066–1071

    Article  PubMed  CAS  Google Scholar 

  • Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD (1995) Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441–1445

    Article  PubMed  CAS  Google Scholar 

  • Goldhirsch A, Coates AS, Colleoni M, Gelber RD (1998a) Radiotherapy and chemotherapy in high-risk breast cancer (letter). N Engl J Med 338:330–331

    PubMed  CAS  Google Scholar 

  • Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD (1998b) Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. J Clin Oncol 16:1358–1362

    PubMed  CAS  Google Scholar 

  • International Breast Cancer Study Group (1997) Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15:1385–1394

    CAS  Google Scholar 

  • Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffler H, Kreienberg R et al (1993) Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 11:454–460

    PubMed  CAS  Google Scholar 

  • Kerbel RS (1997) A cancer therapy resistant to resistance. Nature 390:335–336

    Article  PubMed  CAS  Google Scholar 

  • Levine MN, Bramwell VH, Pritchard KI, Norris GD, Shepherd LE, Abu-Zahra H et al for the National Cancer Institute of Canada Clinical Trials Group (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651–2658

    PubMed  CAS  Google Scholar 

  • Miles D (1997) Breast cancer tumour vaccines. Cancer Treat Rev Suppl 1:S77–S85

    Article  Google Scholar 

  • Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P et al (1996) Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after 16-year median follow-up duration. J Clin Oncol 14:1136–1145

    PubMed  CAS  Google Scholar 

  • Osborne CK (1994) Interactions of tamoxifen with cytotoxic chemotherapy for breast cancer. In: Jordan VC (ed) Long term tamoxifen for breast cancer. University of Wisconsin Press, Madison, pp 181–198

    Google Scholar 

  • Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949–955

    Article  PubMed  CAS  Google Scholar 

  • Pagani O, O’Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM et al (1998) Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632–640

    Article  PubMed  CAS  Google Scholar 

  • Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE et al (1997) Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J Clin Oncol 15:2302–2311

    PubMed  CAS  Google Scholar 

  • Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE et al (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956–962

    Article  PubMed  CAS  Google Scholar 

  • Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR et al (1994) Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 12:2078–2085

    PubMed  CAS  Google Scholar 

  • Rose C, Andersen J, Axelsson C, Blichert-Tort M, Dombernowsky P, Hansen C et al. (1992) A randomized DBCG trial of adjuvant (adj) tamoxifen (TAM)+radiotherapy (RT) vs TAM alone vs TAM+CMF in postmenopausal breast cancer patients (pts) with high risk of recurrence (meeting abstract). Proc ASCO 11:58 (abstr 57)

    Google Scholar 

  • Sjogren S, Inganas M, Lindgren A, Hohnberg L, Bergh J (1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462–469

    PubMed  CAS  Google Scholar 

  • Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B et al (1995) High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13:424–429

    PubMed  CAS  Google Scholar 

  • Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543–1549

    Article  Google Scholar 

  • Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16:994–999

    PubMed  CAS  Google Scholar 

  • Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M et al (1997) Sentinelnode biopsy to avoid axillary dissection in breast cancer with clinically negative lymphnodes. Lancet 349:1864–1867

    Article  PubMed  CAS  Google Scholar 

  • Wils J, Bliss JM, Coombes RC, Woods E, Coombes G, Blijham EH et al for the International Collaborative Cancer Group (ICCG) (1996) A multicentre randomized trial of tamoxifen vs. tamoxifen plus epirubicin in postmenopausal women with node-positive breast cancer. Proc ASCO 15:109 (abstr 101)

    Google Scholar 

  • Zujewski J, Nelson A, Abrams J (1998) Much ado about not enough data; high-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 90:200–209

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. European Institute of Oncology, I-20141, Milan, Italy

    Aron Goldhirsch

  2. International Breast Cancer Study Group, Lugano, Switzerland

    Aron Goldhirsch

  3. University of Pennsylvania Cancer Center, Philadelphia, USA

    John H. Glick

  4. Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard D. Gelber

  5. Center for Tumordetection and Prevention, CH-9006, St. Gallen, Switzerland

    Hans-Jörg Senn

Authors
  1. Aron Goldhirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John H. Glick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard D. Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans-Jörg Senn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum für Tumordiagnostik und Prävention, Rorschacherstrasse 150, CH-9006, St. Gallen, Switzerland

    Hans-Jörg Senn

  2. Dana Farber Cancer Institute Biostatistics, 44 Binney Street, Boston, 02115, USA

    Richard D. Gelber Ph.D

  3. Ospedale Civico, CH-6900, Lugano, Switzerland

    Aron Goldhirsch

  4. Klinik C für Innere Medizin Abteilung für Onkologie und Hämatologie, Kantonsspital St. Gallen, CH-9007, St. Gallen, Switzerland

    Beat Thürlimann

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Goldhirsch, A., Glick, J.H., Gelber, R.D., Senn, HJ. (1998). International Consensus Panel on the Treatment of Primary Breast Cancer V: Update 1998. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45769-2_46

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45769-2_46

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45771-5

  • Online ISBN: 978-3-642-45769-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation